Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-T vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
FDA-approved: Treatment of symptoms and prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity; as an adjunct in COPD exacerbations; prevention of neonatal apnea.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/m L. Maximum: 800 mg/day or 400 mg twice daily.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is approximately 8 hours in healthy adults (range 3-13 hours). In neonates, it is prolonged (20-30 h). In smokers, half-life is reduced to 4-5 h. In patients with hepatic cirrhosis or heart failure, half-life may exceed 24 hours.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4; underwent N-demethylation and oxidation to active metabolites (caffeine and 3-methylxanthine).
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Approximately 90% is eliminated via hepatic metabolism (primarily via CYP1A2, CYP3A4), and about 10% is excreted unchanged in the urine. Renal clearance accounts for <10% of total clearance in adults. Biliary/fecal excretion is minimal (less than 5%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40% bound to plasma proteins, primarily albumin. Binding is saturable and decreases in uremia.
55–65% bound to plasma proteins, primarily albumin.
Approximately 0.45 L/kg (range 0.3-0.7 L/kg). This reflects distribution throughout total body water with some tissue binding.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 96% (well absorbed). Oral sustained-release (SOMOPHYLLIN-T): approximately 90-100% relative to immediate-release. Intravenous: 100%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dose adjustment required in renal impairment. Theophylline pharmacokinetics minimally affected by GFR; however, monitor for accumulation in severe impairment (Cr Cl <10 m L/min) due to altered clearance.
No dose adjustment required for renal impairment.
Child-Pugh Class A: Reduce dose by 50% of normal dose. Child-Pugh Class B: Reduce dose by 70% of normal dose. Child-Pugh Class C: Reduce dose by 80% of normal dose; frequent monitoring of serum levels recommended.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Oral: 6-12 years: 10-16 mg/kg/day (max 400 mg/day) divided every 12 hours. 12-16 years: 10-16 mg/kg/day (max 600 mg/day) divided every 12 hours. Initiate at lower end of dose range and titrate based on therapeutic drug monitoring. Target trough serum concentration: 5-15 mcg/m L.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Elderly patients require cautious dosing: start at 200 mg once daily (or 100 mg twice daily) due to reduced clearance. Titrate slowly with frequent monitoring of serum levels. Target the lower end of therapeutic range (5-10 mcg/m L).
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Risk of serious adverse events including seizures, cardiac arrhythmias, and death, especially with serum levels >20 mcg/m L.,Cautious use in patients with peptic ulcer disease, hyperthyroidism, seizure disorders, and cardiac disease.,Geriatric patients and those with hepatic impairment require dose adjustments.,Drug interactions with fluoroquinolones, macrolides, cimetidine, and allopurinol may increase theophylline levels.,Smoking induces metabolism, requiring higher doses.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation.,History of seizure disorder (relative, based on risk-benefit).,Cardiac arrhythmias (relative).
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid excessive consumption of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase theophylline side effects. Charcoal-broiled foods and high-protein diets may alter theophylline metabolism; maintain consistent intake. No significant interactions with other foods.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
First trimester: Limited data; no increased risk of major congenital anomalies reported in human studies. Second and third trimesters: Use with caution due to potential fetal tachycardia and jitteriness. High doses may lead to neonatal withdrawal. Overall, theophylline is considered relatively low risk compared to other xanthines.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with an M/P ratio of 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability and insomnia have been reported. Benefits of breastfeeding likely outweigh risks at maternal therapeutic doses.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Increased clearance (especially 2nd and 3rd trimesters) may require dose increases to maintain therapeutic levels. Postpartum: Clearance decreases rapidly within 6 weeks, requiring dose reduction to prevent toxicity. Therapeutic drug monitoring recommended.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
SOMOPHYLLIN-T is a sustained-release theophylline formulation. Monitor serum theophylline levels (target 10-20 mcg/m L) to avoid toxicity, especially in patients with hepatic impairment, heart failure, or those on drugs that inhibit CYP1A2 (e.g., cimetidine, fluoroquinolones). The extended-release formulation should not be crushed or chewed. Tachyphylaxis may occur with prolonged use.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take this medication exactly as prescribed, usually every 12 hours, with or without food.,Do not crush, chew, or break the tablet; swallow it whole.,Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase nervousness and palpitations.,Contact your doctor immediately if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not change your dose or stop taking without consulting your doctor, as it may cause worsening of asthma or COPD symptoms.,Inform all healthcare providers that you are taking theophylline, especially before surgery or any new medication.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-T vs AEROLATE SR, answered by our medical review team.
SOMOPHYLLIN-T is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-T and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-T is: Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/m L. Maximum: 800 mg/day or 400 mg twice daily.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-T and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-T is classified as Category C. First trimester: Limited data; no increased risk of major congenital anomalies reported in human studies. Second and third trimesters: Use with caution due to potential fetal tachy. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.